{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"951"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"Population PK analysis was performed using nonlinear mixed effect modeling.","groups":[{"description":"Phase 1: nab-paclitaxel 120-270 mg/m\\^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D. Phase 2: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG000","title":"PK Population"}],"paramType":"NUMBER","populationDescription":"PK population: all participants who received at least one dose of nab-paclitaxel and had evaluable concentration data","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Participants ≥ 6 years: 1-2 minutes prior to the end of infusion [EOI], and 15 minutes, 1, 3, 5, 8, 24, 48, and 72 hours after the EOI. Participants < 6 years: 1-2 minutes prior to the EOI, and 15 minutes, 3, 5, and 24 hours after the EOI.)","title":"Phase 1 and 2 Population PK: Concentration in the Central Compartment at 50% of VMEL (KMEL)","type":"SECONDARY","unitOfMeasure":"μg/L"}